[{"id":"796304d3-46d7-4eb0-aa64-9c9bbe7b7955","acronym":"Pola-R-ICE","url":"https://clinicaltrials.gov/study/NCT04833114","created_at":"2021-04-06T11:55:24.930Z","updated_at":"2025-02-25T14:15:54.989Z","phase":"Phase 3","brief_title":"Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)","source_id_and_acronym":"NCT04833114 - Pola-R-ICE","lead_sponsor":"GWT-TUD GmbH","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement • CD20 negative","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Rituxan (rituximab) • ifosfamide • etoposide IV • Polivy (polatuzumab vedotin-piiq)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 306","initiation":"Initiation: 04/30/2021","start_date":" 04/30/2021","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-18"},{"id":"652fcefb-b53c-4b62-8b35-ac9d0a1fa74e","acronym":"SKYGLO","url":"https://clinicaltrials.gov/study/NCT06047080","created_at":"2023-09-21T14:10:31.989Z","updated_at":"2025-02-25T14:18:19.180Z","phase":"Phase 3","brief_title":"An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma","source_id_and_acronym":"NCT06047080 - SKYGLO","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)"],"overall_status":"Recruiting","enrollment":" Enrollment 1130","initiation":"Initiation: 09/18/2023","start_date":" 09/18/2023","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 02/28/2029","study_completion_date":" 02/28/2029","last_update_posted":"2025-02-17"},{"id":"90ac22c8-dcce-478e-af97-ed4ef0a3b357","acronym":"","url":"https://clinicaltrials.gov/study/NCT04665765","created_at":"2021-01-19T20:43:36.698Z","updated_at":"2025-02-25T14:08:04.780Z","phase":"Phase 2","brief_title":"Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT04665765","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Rituxan (rituximab) • cyclophosphamide • ifosfamide • etoposide IV • Truxima (rituximab-abbs) • Polivy (polatuzumab vedotin-piiq) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 01/18/2021","start_date":" 01/18/2021","primary_txt":" Primary completion: 07/26/2022","primary_completion_date":" 07/26/2022","study_txt":" Completion: 07/08/2025","study_completion_date":" 07/08/2025","last_update_posted":"2025-02-17"},{"id":"f3d0b4ce-a825-4e88-abe6-0a2852f91550","acronym":"SUNMO","url":"https://clinicaltrials.gov/study/NCT05171647","created_at":"2021-12-29T14:53:50.426Z","updated_at":"2025-02-25T14:41:08.199Z","phase":"Phase 3","brief_title":"A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT05171647 - SUNMO","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20 • CD4","pipe":"","alterations":" ","tags":["CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Rituxan (rituximab) • oxaliplatin • Actemra IV (tocilizumab) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 242","initiation":"Initiation: 04/25/2022","start_date":" 04/25/2022","primary_txt":" Primary completion: 05/30/2025","primary_completion_date":" 05/30/2025","study_txt":" Completion: 02/28/2027","study_completion_date":" 02/28/2027","last_update_posted":"2025-02-14"},{"id":"e7cf2c99-6cfe-4015-9ca9-b9a242d379a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04739813","created_at":"2021-02-05T13:56:26.764Z","updated_at":"2025-02-25T16:38:14.078Z","phase":"Phase 1","brief_title":"Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma","source_id_and_acronym":"NCT04739813","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • BCL6 • UGT1A1","pipe":" | ","alterations":" MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement • UGT1A1*1*1 • UGT1A1 mutation","tags":["BCL2 • BCL6 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement • UGT1A1*1*1 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • lenalidomide • Gazyva (obinutuzumab) • prednisone • Polivy (polatuzumab vedotin-piiq)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 07/09/2021","start_date":" 07/09/2021","primary_txt":" Primary completion: 10/29/2025","primary_completion_date":" 10/29/2025","study_txt":" Completion: 10/29/2030","study_completion_date":" 10/29/2030","last_update_posted":"2025-02-06"},{"id":"37db9b88-cfea-407b-b290-ec67bb7844d2","acronym":"EPCORE NHL-5","url":"https://clinicaltrials.gov/study/NCT05283720","created_at":"2022-03-17T12:53:27.504Z","updated_at":"2025-02-25T16:54:10.677Z","phase":"Phase 2","brief_title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05283720 - EPCORE NHL-5","lead_sponsor":"Genmab","biomarkers":" BCL2 • CD20 • CCND1 • BCL6","pipe":" | ","alterations":" Chr t(11;14)","tags":["BCL2 • CD20 • CCND1 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • prednisone • Jaypirca (pirtobrutinib) • Epkinly (epcoritamab-bysp) • Polivy (polatuzumab vedotin-piiq) • golcadomide (CC-99282)"],"overall_status":"Recruiting","enrollment":" Enrollment 622","initiation":"Initiation: 06/14/2022","start_date":" 06/14/2022","primary_txt":" Primary completion: 11/01/2032","primary_completion_date":" 11/01/2032","study_txt":" Completion: 11/01/2032","study_completion_date":" 11/01/2032","last_update_posted":"2025-02-04"},{"id":"eb87323c-0942-4abb-b43f-af01b1dff7f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT06015880","created_at":"2023-12-26T19:17:43.252Z","updated_at":"2025-02-25T17:32:19.406Z","phase":"Phase 1","brief_title":"Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT06015880","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IFNG • CD79B • CD4","pipe":" | ","alterations":" CD79B expression","tags":["IFNG • CD79B • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD79B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/20/2024","start_date":" 05/20/2024","primary_txt":" Primary completion: 06/29/2026","primary_completion_date":" 06/29/2026","study_txt":" Completion: 06/29/2026","study_completion_date":" 06/29/2026","last_update_posted":"2025-01-30"},{"id":"82776520-b06e-46e0-b799-6acc9cecb384","acronym":"","url":"https://clinicaltrials.gov/study/NCT05615636","created_at":"2022-11-14T14:58:16.761Z","updated_at":"2024-07-02T16:34:36.912Z","phase":"Phase 2","brief_title":"A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL","source_id_and_acronym":"NCT05615636","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Monjuvi (tafasitamab-cxix) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 04/28/2023","start_date":" 04/28/2023","primary_txt":" Primary completion: 08/19/2025","primary_completion_date":" 08/19/2025","study_txt":" Completion: 08/19/2027","study_completion_date":" 08/19/2027","last_update_posted":"2024-06-10"},{"id":"eaa4b0cc-1c12-4c08-bcab-722de6ee0d54","acronym":"GO40554","url":"https://clinicaltrials.gov/study/NCT03677154","created_at":"2021-01-18T18:02:02.678Z","updated_at":"2024-07-02T16:34:59.656Z","phase":"Phase 1/2","brief_title":"Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT03677154 - GO40554","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Actemra IV (tocilizumab) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 188","initiation":"Initiation: 05/23/2019","start_date":" 05/23/2019","primary_txt":" Primary completion: 08/03/2025","primary_completion_date":" 08/03/2025","study_txt":" Completion: 08/03/2025","study_completion_date":" 08/03/2025","last_update_posted":"2024-05-31"},{"id":"2bfa926d-ebd9-4305-97d7-e0484514b282","acronym":"BO42203","url":"https://clinicaltrials.gov/study/NCT04790903","created_at":"2021-03-10T12:54:53.574Z","updated_at":"2024-07-02T16:34:59.975Z","phase":"Phase 1","brief_title":"A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)","source_id_and_acronym":"NCT04790903 - BO42203","lead_sponsor":"Hoffmann-La Roche","biomarkers":" BCL2 • CD20","pipe":" | ","alterations":" CD20 positive","tags":["BCL2 • CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 07/02/2021","start_date":" 07/02/2021","primary_txt":" Primary completion: 05/21/2024","primary_completion_date":" 05/21/2024","study_txt":" Completion: 05/21/2024","study_completion_date":" 05/21/2024","last_update_posted":"2024-05-30"},{"id":"099b5bf4-7bd1-4b6b-9199-1c53110e04ad","acronym":"DALY 2-EU","url":"https://clinicaltrials.gov/study/NCT04844866","created_at":"2021-04-14T11:52:59.944Z","updated_at":"2024-07-02T16:35:06.971Z","phase":"Phase 2","brief_title":"Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients","source_id_and_acronym":"NCT04844866 - DALY 2-EU","lead_sponsor":"Miltenyi Biomedicine GmbH","biomarkers":" BCL2 • CD19 • BCL6","pipe":" | ","alterations":" CD19 expression • BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • CD19 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Rituxan (rituximab) • oxaliplatin • bendamustine • Polivy (polatuzumab vedotin-piiq) • zamtocabtagene autoleucel (MB-CART2019.1)"],"overall_status":"Recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 08/18/2021","start_date":" 08/18/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 07/31/2027","study_completion_date":" 07/31/2027","last_update_posted":"2024-04-30"},{"id":"f0a52ee0-440d-49ea-b590-78924884d90a","acronym":"NP40126","url":"https://clinicaltrials.gov/study/NCT03467373","created_at":"2021-01-18T17:05:19.784Z","updated_at":"2024-07-02T16:35:07.282Z","phase":"Phase 1","brief_title":"A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL","source_id_and_acronym":"NCT03467373 - NP40126","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • Gazyva (obinutuzumab) • cyclophosphamide • vincristine • prednisone • Actemra IV (tocilizumab) • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 172","initiation":"Initiation: 03/13/2018","start_date":" 03/13/2018","primary_txt":" Primary completion: 10/30/2024","primary_completion_date":" 10/30/2024","study_txt":" Completion: 10/30/2024","study_completion_date":" 10/30/2024","last_update_posted":"2024-04-26"},{"id":"acc063ee-1af6-4a9d-b0aa-6e09d71310a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04231877","created_at":"2021-01-18T20:35:12.972Z","updated_at":"2024-07-02T16:35:07.534Z","phase":"Phase 1","brief_title":"Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma","source_id_and_acronym":"NCT04231877","lead_sponsor":"University of Washington","biomarkers":" ALK • BCL2 • BCL6","pipe":" | ","alterations":" BCL6 translocation","tags":["ALK • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • prednisone • daunorubicin • Truxima (rituximab-abbs) • Polivy (polatuzumab vedotin-piiq) • Riabni (rituximab-arrx) • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Suspended","enrollment":" Enrollment 50","initiation":"Initiation: 10/27/2020","start_date":" 10/27/2020","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-04-25"},{"id":"defc9de3-2fea-4a63-992f-0da7e4f79121","acronym":"","url":"https://clinicaltrials.gov/study/NCT04594798","created_at":"2021-01-19T20:29:12.188Z","updated_at":"2024-07-02T16:35:09.366Z","phase":"Phase 2","brief_title":"A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL","source_id_and_acronym":"NCT04594798","lead_sponsor":"University of Rochester","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 09/20/2021","start_date":" 09/20/2021","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-04-16"},{"id":"59ce27ae-769a-4818-90df-fa3d4bf1853a","acronym":"NP39488","url":"https://clinicaltrials.gov/study/NCT03533283","created_at":"2021-01-18T17:24:16.887Z","updated_at":"2024-07-02T16:35:09.948Z","phase":"Phase 1/2","brief_title":"An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT03533283 - NP39488","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 05/08/2018","start_date":" 05/08/2018","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2024-04-12"},{"id":"78e30890-7167-48ec-b8de-daa0c7ba716c","acronym":"POLARIX","url":"https://clinicaltrials.gov/study/NCT03274492","created_at":"2021-01-18T16:10:20.305Z","updated_at":"2024-07-02T16:35:10.168Z","phase":"Phase 3","brief_title":"A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT03274492 - POLARIX","lead_sponsor":"Hoffmann-La Roche","biomarkers":" ALK • BCL2 • CD20 • BCL6","pipe":" | ","alterations":" ALK positive • CD20 positive • BCL6 rearrangement","tags":["ALK • BCL2 • CD20 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • CD20 positive • BCL6 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Polivy (polatuzumab vedotin-piiq) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 11/16/2017","start_date":" 11/16/2017","primary_txt":" Primary completion: 06/27/2024","primary_completion_date":" 06/27/2024","study_txt":" Completion: 06/27/2024","study_completion_date":" 06/27/2024","last_update_posted":"2024-04-11"},{"id":"3d6f76a8-140c-4d3b-88bd-50b84fd68679","acronym":"PORTAL","url":"https://clinicaltrials.gov/study/NCT06071871","created_at":"2023-10-10T15:12:02.592Z","updated_at":"2024-07-02T16:35:12.168Z","phase":"Phase 2","brief_title":"A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab as a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma","source_id_and_acronym":"NCT06071871 - PORTAL","lead_sponsor":"University College, London","biomarkers":" MYC • BCL2 • CD20 • BCL6","pipe":" | ","alterations":" CD20 positive","tags":["MYC • BCL2 • CD20 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 99","initiation":"Initiation: 04/30/2024","start_date":" 04/30/2024","primary_txt":" Primary completion: 01/31/2027","primary_completion_date":" 01/31/2027","study_txt":" Completion: 07/31/2028","study_completion_date":" 07/31/2028","last_update_posted":"2024-04-01"},{"id":"6aea670a-703a-4441-a9ff-cf2cf5b73ea7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04479267","created_at":"2021-01-18T21:30:41.002Z","updated_at":"2024-07-02T16:35:13.759Z","phase":"Phase 2","brief_title":"Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma","source_id_and_acronym":"NCT04479267","lead_sponsor":"Barbara Ann Karmanos Cancer Institute","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" MYC overexpression • MYC expression • BCL6 rearrangement • BCL2 rearrangement","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC overexpression • MYC expression • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Truxima (rituximab-abbs) • Polivy (polatuzumab vedotin-piiq) • Riabni (rituximab-arrx) • cyclophosphamide intravenous • methylprednisolone sodium succinate • prednisolone"],"overall_status":"Recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 08/21/2020","start_date":" 08/21/2020","primary_txt":" Primary completion: 11/15/2025","primary_completion_date":" 11/15/2025","study_txt":" Completion: 11/15/2026","study_completion_date":" 11/15/2026","last_update_posted":"2024-03-20"},{"id":"f60330f9-debe-4577-9880-a414e6b5d3b6","acronym":"GRAIL","url":"https://clinicaltrials.gov/study/NCT06050694","created_at":"2023-09-22T14:10:51.469Z","updated_at":"2024-07-02T16:35:15.177Z","phase":"Phase 2","brief_title":"Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)","source_id_and_acronym":"NCT06050694 - GRAIL","lead_sponsor":"University Health Network, Toronto","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2024-03-12"},{"id":"69353146-1df5-48d8-b94c-7555527cfb6e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05800366","created_at":"2023-04-05T14:03:39.999Z","updated_at":"2024-07-02T16:35:17.942Z","phase":"Phase 2","brief_title":"A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT05800366","lead_sponsor":"Jennifer Crombie, MD","biomarkers":" ALK • BCL2 • CD20 • BCL6","pipe":" | ","alterations":" ALK positive • CD20 positive • MYC translocation","tags":["ALK • BCL2 • CD20 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • CD20 positive • MYC translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 04/06/2023","start_date":" 04/06/2023","primary_txt":" Primary completion: 09/15/2026","primary_completion_date":" 09/15/2026","study_txt":" Completion: 09/15/2029","study_completion_date":" 09/15/2029","last_update_posted":"2024-02-23"},{"id":"14041a82-573a-4b07-85ab-c7be6f6788c2","acronym":"POLAR BEAR","url":"https://clinicaltrials.gov/study/NCT04332822","created_at":"2021-01-18T20:58:50.332Z","updated_at":"2024-07-02T16:35:19.585Z","phase":"Phase 3","brief_title":"A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma","source_id_and_acronym":"NCT04332822 - POLAR BEAR","lead_sponsor":"Nordic Lymphoma Group","biomarkers":" MYC • BCL2","pipe":" | ","alterations":" MYC rearrangement + BCL2 rearrangement • MYC rearrangement • BCL2 rearrangement","tags":["MYC • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement + BCL2 rearrangement • MYC rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • Polivy (polatuzumab vedotin-piiq)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 08/19/2020","start_date":" 08/19/2020","primary_txt":" Primary completion: 12/28/2025","primary_completion_date":" 12/28/2025","study_txt":" Completion: 12/28/2028","study_completion_date":" 12/28/2028","last_update_posted":"2024-02-13"},{"id":"6484b4c0-0f7f-4382-8109-69c83a36847e","acronym":"GO40515","url":"https://clinicaltrials.gov/study/NCT03677141","created_at":"2021-01-18T18:02:02.169Z","updated_at":"2024-07-02T16:35:20.830Z","phase":"Phase 1/2","brief_title":"A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT03677141 - GO40515","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Actemra IV (tocilizumab) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 117","initiation":"Initiation: 03/08/2019","start_date":" 03/08/2019","primary_txt":" Primary completion: 10/12/2023","primary_completion_date":" 10/12/2023","study_txt":" Completion: 10/12/2023","study_completion_date":" 10/12/2023","last_update_posted":"2024-02-06"},{"id":"af5de0f1-75cb-4dd2-ab2d-32287b9a5c66","acronym":"","url":"https://clinicaltrials.gov/study/NCT06040320","created_at":"2023-09-15T18:10:21.194Z","updated_at":"2024-07-02T16:35:23.496Z","phase":"Phase 1/2","brief_title":"Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)","source_id_and_acronym":"NCT06040320","lead_sponsor":"Washington University School of Medicine","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Polivy (polatuzumab vedotin-piiq)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 10/04/2023","start_date":" 10/04/2023","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2031","study_completion_date":" 05/31/2031","last_update_posted":"2024-01-15"},{"id":"bac456cb-b78b-4934-9ea0-909a41338c0d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04659044","created_at":"2021-01-19T20:42:10.154Z","updated_at":"2024-07-02T16:35:24.240Z","phase":"Phase 2","brief_title":"Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma","source_id_and_acronym":"NCT04659044","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" CCND1","pipe":" | ","alterations":" Chr t(11;14)","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • Truxima (rituximab-abbs) • Rituxan Hycela (rituximab/hyaluronidase) • Polivy (polatuzumab vedotin-piiq) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 04/01/2021","start_date":" 04/01/2021","primary_txt":" Primary completion: 04/04/2027","primary_completion_date":" 04/04/2027","study_txt":" Completion: 04/01/2029","study_completion_date":" 04/01/2029","last_update_posted":"2024-01-08"}]